All In Biotech

Drug Trial Radar · NCT05550337

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, THREE-ARM, PLACEBO CONTROLLED, PARALLEL-DESIGN GROUP STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE COMPARING TRIFAROTENE CREAM, 0.005% (TEVA PHARMACEUTICALS, INC. TO AKLIEF ® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., USA), IN THE TREATMENT OF ACNE VULGARIS

Last checked: Nov 19, 2026Latest source record: Sep 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 807 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

807

Actual

Start

Sep 19, 2022

Primary completion

May 9, 2023

Study completion May 9, 2023

Sponsor

Lead sponsor
Teva Pharmaceuticals USATeva (TEVA)
Sponsor type
Industry
Collaborators
Teva Pharmaceuticals, Inc.
First posted
Sep 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • Trifarotene 0.005 % Topical CreamDrug

    Cream

  • AKLIEF®Drug

    Cream

  • PlaceboDrug

    Cream

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Change in Inflammatory Lesion CountsTime frame: Baseline and 12 Weeks
  2. Primary Change in Non-Inflammatory Lesion CountTime frame: Baseline and 12 Weeks

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Site 10011

    West Covina, California

  • Site 10001

    Brandon, Florida

  • Site 10003

    Fort Lauderdale, Florida

  • Site 10004

    Miami, Florida

  • Site 10005

    Miramar, Florida

  • Site 10002

    Tampa, Florida

  • Site 10012

    Baton Rouge, Louisiana

  • Site 10013

    Baton Rouge, Louisiana

  • Site 10011

    New Orleans, Louisiana

  • Site 10008

    Las Cruces, New Mexico

  • Site 10010

    Saint Clair, Pennsylvania

  • Site 10009

    Dallas, Texas

  • Site 10006

    El Paso, Texas

  • Site 10007

    El Paso, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.